Myocardial Infarction News and Research

RSS

Obicetrapib slashes LDL cholesterol by over 30% in high-risk heart patients

A large multinational trial published in the New England Journal of Medicine shows that obicetrapib significantly lowers LDL cholesterol in high-risk cardiovascular patients. The CETP inhibitor also improved key lipid parameters with no major safety concerns, supporting its role in future combination therapies.

8 May 2025

Study shows no connection between PM2.5 spikes and major cardiovascular events

A Danish cohort study investigated whether long-term exposure to repeated monthly peaks of fine particulate matter (PM2.5) raises the risk of major adverse cardiovascular events. Despite higher PM2.5 peak exposure among affected individuals, no significant association with cardiovascular risk was found.

7 May 2025

Phthalates in plastics linked to over 350,000 heart deaths worldwide

A global modeling study in eBioMedicine links phthalate exposure from plastics, especially DEHP metabolites, to over 356,000 cardiovascular deaths in 2018. Exposure was highest in Asia, the Middle East, and Africa, disproportionately affecting lower-income countries.

4 May 2025

Study shows safe outcomes for PCI performed in ambulatory surgery centers

The first study evaluating Medicare patients undergoing percutaneous coronary intervention (PCI) in ambulatory surgery centers (ASCs) demonstrated good safety outcomes, such as mortality and adverse event rates at 30 days, compared to outpatient hospital departments, but were less likely to use certain technologies.

2 May 2025

New studies link increased heart disease risk to tobacco and cannabis use

New clinical results from multiple studies show coronary heart disease death associated with tobacco use is anticipated to rise up to 40% in the next five years and people with cannabis use disorder are 50% more likely to experience cardiogenic shock, acute myocardial infarction, and arrhythmias.

2 May 2025

Study: One in four early cardiogenic shock patients experience worse outcomes

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including care escalation, CS deterioration, or in-hospital mortality.

2 May 2025

Intravenous therapy promotes survival of heart muscle cells after a heart attack

Researchers have developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure.

25 Apr 2025

Chitosan clears microplastics from the gut in rats within days

A study in rats found that ingesting chitosan, a dietary fiber from shells, significantly increased the fecal excretion rate and decreased the gut retention time of polyethylene microplastics. This suggests chitosan could potentially help mitigate microplastic accumulation in the digestive system.

24 Apr 2025

Researchers uncover link between heart attack severity and circadian rhythm

The molecular mechanism behind why heart attacks can vary in severity depending on the time of day has been uncovered by researchers at UTHealth Houston, potentially paving the way for innovative treatments that align with the natural circadian rhythm.

23 Apr 2025

Gut microbiome pattern predicts future heart attack risk in coronary heart disease patients

A specific gut microbiota pattern was found to predict new cardiovascular events in patients with coronary heart disease, based on data from the CORDIOPREV study. Researchers developed a microbiota-based risk score that may improve secondary prevention.

21 Apr 2025

Redefining cardiovascular medicine through the lens of sncRNAs

In a transformative review, small noncoding RNAs (sncRNAs) have emerged as pivotal regulators in the complex landscape of cardiovascular diseases.

20 Apr 2025

Early combination treatment can prevent heart attacks and save lives

Patients who receive an add-on medication soon after a heart attack have a significantly better prognosis than those who receive it later, or not all.

16 Apr 2025

Low vitamin D levels damage erectile health via superoxide surge, study finds

Vitamin D deficiency directly causes erectile dysfunction by increasing superoxide and reducing protective SLPI levels, as shown in human tissue and animal models. This breakthrough reveals why low vitamin D may lead to poor sexual health and resistance to standard ED treatments.

15 Apr 2025

Early combination therapy after heart attack reduces risk of recurrence and death

Cardiovascular disease is by far the most common cause of death worldwide, and myocardial infarction is the most common acute event.

14 Apr 2025

Genetic tendency to sedentary behavior linked to higher heart disease risk

Although sedentary behavior may be an evolutionarily selected trait, it is still important to try to be physically active, says a new study conducted at the University of Jyväskylä, Finland.

8 Apr 2025

Compound heatwaves linked to increased cardiac deaths

Cardiac deaths increase significantly during compound heatwaves-heatwaves where temperatures are elevated both during the day and overnight-according to a new study in JACC, the flagship journal of the American College of Cardiology.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

Five lifestyle changes by 50 can add a decade to your life, global study finds

Study estimates the global lifetime risk and benefits of modifying cardiovascular risk factors like hypertension, smoking, and obesity by age 50, showing significant improvements in both life expectancy and quality of life. It highlights the importance of early intervention and midlife changes in preventing cardiovascular disease and mortality.

31 Mar 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

Rivaroxaban shown to be a viable alternative to warfarin for left ventricular thrombus

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar patients who received standard treatment with warfarin, an older blood-thinning drug.

29 Mar 2025